Boehringer Ingelheim pays $650 mn to settle lawsuits

May 28, 2014

German pharmaceuticals maker Boehringer Ingelheim said Wednesday it has agreed to pay $650 million to settle around 4,000 lawsuits relating to its blood-thinning drug Pradaxa.

"Boehringer Ingelheim announced today that the has reached a comprehensive of state and federal cases in the US litigation regarding Pradaxa," it said in a statement.

Boehringer Ingelheim insisted that it continued to stand behind the drug, which is used to prevent and stroke by thinning the blood.

But Pradaxa has been blamed for more than 500 deaths caused by uncontrolled bleeding.

The German group insisted that the US Food and Drug Administration (FDA) has reaffirmed the "positive benefit-risk profile of Pradaxa."

"The settlement enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives and allows the company to avoid the distraction and uncertainty of lengthy litigation. The settlement was closed at $650 million or approximately 470 million euros," the statement said.

The company said there were approximately 4,000 claims that it was seeking to resolve with this settlement.

"Boehringer Ingelheim expects most, if not all, of the plaintiffs to accept the terms of the settlement and Boehringer Ingelheim will vigorously defend against those who do not," the statement said.

"Notwithstanding our strong belief that we would prevail in these lawsuits, this settlement allows our company to avoid the distraction and uncertainty of protracted litigation over years and years," said the company's legal chief, Andreas Neumann.

Explore further: Lilly, Boehringer collaborate on diabetes drugs

Related Stories

Lilly, Boehringer collaborate on diabetes drugs

January 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

New blood thinner beats older drug for vein clots

February 20, 2013

(HealthDay)—People who need to take a blood thinner because they've had a clot in the deep veins of their legs appear to do better with the new drug Pradaxa (dibigatran) than with the older drug warfarin, researchers report.

French families file suit over alleged blood-thinner deaths

October 9, 2013

The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.

Recommended for you

Treatment options for opioid addiction are expanding

August 10, 2016

In the past two decades, the devastation associated with opioid addiction has escaped the relative confines of the inner city and extended to suburban and rural America. Due in large part to the proliferation of prescription ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

FDA bolsters warnings about class of antibiotics

July 26, 2016

(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.